Abstract
BackgroundLate cardiac toxicities caused by (particularly left-sided) breast radiotherapy (RT) are now recognized as rare but relevant sequelae, which has prompted research on risk structure identification and definition of threshold doses to heart subvolumes. The aim of the present review was to critically discuss the clinical evidence on late cardiac reactions based on dose-dependent outcome reports for mean heart doses as well as doses to cardiac substructures.MethodsA literature review was performed to examine clinical evidence on radiation-induced heart toxicities. Mean heart doses and doses to cardiac substructures were focused upon based on dose-dependent outcome reports. Furthermore, an overview of radiation techniques for heart protection is given and non-radiotherapeutic aspects of cardiotoxicity in the multimodal setting of breast cancer treatment are discussed.ResultsBased on available findings, the DEGRO breast cancer expert panel recommends the following constraints: mean heart dose <2.5 Gy; DmeanLV (mean dose left ventricle) < 3 Gy; V5LV (volume of LV receiving ≥5 Gy) < 17%; V23LV (volume of LV receiving ≥23 Gy) < 5%; DmeanLAD (mean dose left descending artery) < 10 Gy; V30LAD (volume of LAD receiving ≥30 Gy) < 2%; V40LAD (volume of LAD receiving ≥40 Gy) < 1%.ConclusionIn addition to mean heart dose, breast cancer RT treatment planning should also include constraints for cardiac subvolumes such as LV and LAD. The given constraints serve as a clinicians’ aid for ensuring adequate heart protection. The individual decision between sufficient protection of cardiac structures versus optimal target volume coverage remains in the physician’s hand. The risk of breast cancer-specific mortality and a patient’s cardiac risk factors must be individually weighed up against the risk of radiation-induced cardiotoxicity.
Highlights
Late cardiac toxicities caused by breast radiotherapy (RT) are recognized as rare but relevant sequelae, which has prompted research on risk structure identification and definition of threshold doses to heart subvolumes
In early trials including breast RT, an increase in the number of cardiac deaths was observed [4] and cardiac mortality was higher in left-sided breast cancer patients than in right-sided disease [5,6,7]
The authors found an increase in clinically significant coronary artery stenoses in the predefined hotspot areas in patients who underwent left-sided whole-breast irradiation (WBI)/chest wall RT compared to patients who did not receive RT to these areas
Summary
Late cardiac toxicities caused by ( left-sided) breast radiotherapy (RT) are recognized as rare but relevant sequelae, which has prompted research on risk structure identification and definition of threshold doses to heart subvolumes. In early trials including breast RT, an increase in the number of cardiac deaths was observed [4] and cardiac mortality was higher in left-sided breast cancer patients than in right-sided disease [5,6,7] These trials predominantly used older RT techniques, resulting in considerable doses to heart subvolumes [6,7,8,9]. Taylor et al comparatively analyzed mean heart doses from left tangential RT to cardiac structures over several decades, and described reductions in mean heart dose from 13.3 Gy in the 1970s, to 4.7 Gy in the 1990s, and 2.3 Gy in 2006 [10,11,12] This decrease seems to have resulted in a very low risk of death caused by radiation-induced heart disease (RIHD), at least for women without cardiac risk factors [13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
